The core problem, according to the authors, is that assessment of PIH severity currently depends exclusively on visual inspection and patient self-reporting. Both approaches are vulnerable to perception bias, and both can be strongly influenced by ambient lighting conditions, which vary enormously between examination rooms, clinics, and research settings. Unlike many other dermatologic disorders, PIH lacks a standardized clinical scale for assessment, and this absence creates inconsistencies in evaluating disease progression and treatment outcomes. Two clinicians looking at the same lesion may disagree on whether it has lightened, and a patient’s own sense of improvement may not align with what a physician observes. In clinical trials, this subjectivity can blur the signal that researchers are trying to detect, making it harder to demonstrate whether an experimental therapy actually works.

The diagnostic challenges associated with pigmentary disorders more broadly highlight the limitations of subjective visual assessment and support the development of standardized, quantitative methods. Standardized quantitative measurements for PIH would ensure accurate, reproducible, and unbiased assessments regardless of external influences such as lighting or observer expectation. The authors emphasize that objective assessment is particularly important for monitoring therapeutic response over time and for improving the consistency of outcomes in clinical trials evaluating PIH interventions. There is also a counseling dimension: measurable, objective evidence of pigmentary improvement would allow clinicians to give patients concrete feedback, enabling direct and accurate measurement of patient outcomes rather than vague reassurances that a lesion is fading.

Other objective tools do exist. Reflectance confocal microscopy can image pigment at the cellular level, dermoscopy magnifies surface structures, and spectrophotometry can decompose reflected light into its spectral components. Each of these techniques provides valuable pigmentary or structural information. Yet the research letter argues that colorimetry is especially well suited for PIH assessment because it is noninvasive, practical, reproducible, and capable of providing quantitative measurements of pigmentation that can be easily tracked longitudinally. In other words, it occupies a practical middle ground: more objective than the eye, but far simpler and cheaper to deploy in routine practice than advanced imaging platforms.

Colorimetry works by measuring the intensity of light reflectance from the skin, converting what the eye perceives as color into objective numerical data on pigmentation and erythema. The technique has a long pedigree in skin color metrics. It expresses color in three values, corresponding to lightness on a white-to-black axis, a red-to-green axis, and a yellow-to-blue axis, within a three-dimensional color space. This tristimulus representation allows any skin color to be plotted as a point in a defined coordinate system, so that changes over time can be expressed as precise numerical shifts rather than subjective impressions. A fading brown patch, for example, would show a measurable increase in the lightness value, and the magnitude of that shift can be compared across patients, visits, and studies.

The track record of colorimetry in pigmentary research is substantial. It has been used to measure pigmentary involvement in PIH treatment studies, including a landmark trial of topical tretinoin for hyperpigmented lesions caused by cutaneous inflammation in Black patients, published in the New England Journal of Medicine in the 1990s. It has also featured in PIH models that assessed histologic, clinical, spectroscopic, and colorimetric traits in parallel, allowing researchers to correlate what the device measured with what was happening in the skin itself. Beyond PIH, colorimetry has been applied to broader pigmentary disorders, including melasma and vitiligo, where it has been used to track skin lightening and repigmentation over time. The authors argue that this history of successful application in related conditions further supports its utility as a standardized tool for monitoring pigmentary changes longitudinally in PIH specifically.

The vision implicit in the research letter is a clinical scale for PIH anchored in colorimetric values rather than photographic comparisons or ordinal grading by eye. Such a scale would transform how the severity of the condition is communicated and studied. Instead of describing a lesion as mild, moderate, or severe, clinicians could report a lightness value and its deviation from the patient’s baseline skin color, with defined thresholds separating grades of severity. Treatment response could be expressed as the rate of change in those values, giving trials a continuous, statistically powerful endpoint. Because the measurements are numerical, they could be pooled across centers and populations, something that subjective grading has never reliably achieved.

The authors are candid about the hurdles that stand between this vision and routine practice. The cost and availability of colorimetric instruments remain barriers, particularly in resource-limited settings, and operator training is required to obtain consistent readings. Integrating these measurements into established clinical workflows is another practical challenge, since clinic visits are already time-pressured. More fundamentally, colorimetric measurements may be influenced by baseline pigmentation, melanin content, and device-specific calibration, all of which can affect measurement accuracy across varying skin tones and ethnic populations. A device calibrated against one reference population may not perform identically on another, and the very patients who stand to benefit most from objective PIH assessment, those with darker skin types, are the ones for whom calibration issues could be most consequential.

For these reasons, the research letter calls for future studies to validate colorimetric measurements in diverse populations and to assess whether reference ranges are needed. Establishing normative values across the full spectrum of skin tones would be a prerequisite for any scale that aspires to universal use. The authors, a team of dermatology researchers and clinicians affiliated with Texas Tech University Health Sciences Center, Texas Tech Health Sciences Center El Paso, and the Westlake Dermatology Clinical Research Center, report no funding source and no conflicts of interest, and the study received an ethics exemption as a research letter that generated no new datasets.

The significance of the argument extends beyond a single condition. PIH is a frequent sequela of acne, eczema, infections, cosmetic procedures, and injuries, and it disproportionately affects people of color, a population that has historically been underrepresented in dermatologic research. A validated, objective scale would not only improve individual patient care but also raise the methodological quality of the trials that test new treatments, potentially accelerating the development of therapies for a condition that currently has no standardized way to measure its own severity. Colorimetry is not a new technology, but applying it systematically to PIH could be the step that turns a stubbornly subjective clinical problem into a quantitatively tractable one. As the authors suggest, the tools already exist; what is needed now is the validation work to build a scale that clinicians and regulators can trust.

Subject of Research: Using colorimetry to develop an objective clinical scale for post-inflammatory hyperpigmentation

Article Title: The potential of colorimetry in developing a clinical scale for post-inflammatory hyperpigmentation

Article References: Verma, K. K., Goldstein, D. R., Friedmann, D. P., & Tarbox, M. B. (2026). The potential of colorimetry in developing a clinical scale for post-inflammatory hyperpigmentation. Archives of Dermatological Research, 318(1), Article 403. https://doi.org/10.1007/s00403-026-04935-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04935-7

Keywords: post-inflammatory hyperpigmentation, colorimetry, dermatology, skin pigmentation, clinical scale, melanin, spectrophotometry, Fitzpatrick skin type, treatment outcome, quantitative assessment, melasma, vitiligo

The biological target is tyrosinase, the copper-containing enzyme that acts as the gatekeeper of melanogenesis, the biochemical pathway that produces melanin. Tyrosinase catalyzes two critical early steps: converting L-tyrosine into L-DOPA, and then oxidizing L-DOPA into dopaquinone, the precursor from which skin ultimately builds the dark pigments eumelanin and pheomelanin. Because this enzyme sits at the rate-limiting position of the pathway, blocking it has become the dominant strategy for treating hyperpigmentation disorders such as melasma, age spots, and freckles. Yet the current arsenal is imperfect. Hydroquinone, long considered the gold-standard depigmenting agent, carries risks of skin irritation and a disfiguring condition called exogenous ochronosis, and its use in cosmetics is restricted over carcinogenicity concerns. Arbutin and kojic acid are safer but less effective and notoriously unstable in formulation.

That gap has pushed researchers toward peptides, short chains of amino acids that can inhibit tyrosinase through several sequence-dependent routes: competing with substrate for the active site, chelating the copper ions the enzyme needs, or dialing down the genetic program that manufactures the pigment machinery in the first place. The team behind the new study, led by Papassara Sangtanoo and Piroonporn Srimongkol of Chulalongkorn University, reasoned that black ginger rhizomes, despite being a modest protein source, might harbor such peptides. Prior work had shown that the plant contains detectable endogenous peptides, and related species in the ginger family had already yielded tyrosinase-blocking sequences.

The researchers began by extracting crude protein from fresh rhizomes collected in Chiang Rai, Thailand, confirming the plant’s identity through herbarium authentication. They then deployed bromelain, a pineapple-derived enzyme prized for its mild processing conditions, to chop the protein into peptides. Screening revealed a striking size effect: the smaller the fragments, the stronger the inhibition. The fraction containing peptides below 0.65 kilodaltons suppressed tyrosinase with half-maximal inhibitory concentrations of roughly 3 milligrams per milliliter, an order of magnitude more potent than the crude protein itself. Reversed-phase chromatography on that fraction concentrated the activity further, with one sub-fraction showing inhibition at microgram-per-milliliter levels.

Mass spectrometry then delivered the payoff: two sequence-defined peptides, christened YQ-7 (YGRGPIQ) and YA-9 (YNYGPAGQA). Both begin with tyrosine, an aromatic residue that structural studies have repeatedly implicated in tyrosinase binding, and YA-9 carries two tyrosines to YQ-7’s one. When the team chemically synthesized both peptides and tested them against purified mushroom tyrosinase, the sequences retained their activity. YA-9 emerged as the stronger inhibitor, achieving an IC50 of 0.56 millimolar against the monophenolase reaction, while YQ-7 came in at 1.20 millimolar. Bioinformatic screening with the ToxinPred server predicted both peptides to be non-toxic, an encouraging early safety signal for cosmetic applications.

Enzyme kinetics revealed how the peptides work. Lineweaver-Burk analysis showed that increasing peptide concentrations raised the apparent Michaelis constant without changing the maximum reaction velocity, the classic signature of competitive inhibition. In other words, the peptides wedge themselves into the substrate-binding site, physically blocking L-tyrosine and L-DOPA access to the catalytic copper center. Molecular docking against the crystal structure of mushroom tyrosinase corroborated this picture, placing both peptides within the active-site pocket where they form hydrogen bonds with residues such as Asn260 and Arg268, hydrophobic contacts with Val283 and Leu275, and pi-stacking interactions with His263 and Phe264, all flanking the binuclear copper cluster.

The critical question was whether this enzyme-level activity translated into living cells. Testing in B16F10 melanoma cells, a standard model of constitutive melanogenesis, the team found that both peptides reduced intracellular tyrosinase activity and melanin content in a concentration-dependent manner, at levels where more than 80 percent of cells remained viable. At the highest dose of 500 micromolar, melanin content fell to roughly 73 percent of untreated levels for YQ-7 and 75 percent for YA-9. Gene expression analysis by quantitative PCR showed the strongest and most consistent suppression of the tyrosinase gene itself, and Western blotting confirmed concentration-dependent declines in tyrosinase and TRP-1 proteins, with YQ-7 driving tyrosinase protein down to about 23 percent of control levels at the highest dose.

Intriguingly, the molecular responses were not uniformly linear. TRP-2 protein levels fluctuated non-monotonically across concentrations, and MITF, the master transcription factor governing the melanogenic program, showed downward trends that never fell clearly below untreated levels. The authors interpret these inconsistencies as evidence that melanogenesis is controlled by layered, dose-sensitive regulatory networks, including the canonical MITF pathway and alternative routes such as p38 MAPK signaling, and caution that protein abundance, enzyme activity, and cumulative melanin represent distinct biological levels that need not change in lockstep. The findings suggest the peptides act both directly on the enzyme and more broadly on the cellular pigment machinery, though disentangling the relative contributions will require further pathway-specific work.

The final translational test came in zebrafish embryos, a transparent vertebrate model widely used to screen pigmentation modifiers. YA-9, chosen for its superior potency, proved remarkably safe: mortality stayed below 5 percent across all tested concentrations from 20 to 100 micromolar, with developmental abnormalities under 3 percent, against a toxic control that killed nearly 39 percent of embryos. But it failed to significantly lighten the embryos. Relative melanin content dropped only slightly, from a normalized value of 1.00 in controls to 0.81 at the highest dose, while the positive control phenylthiourea cut melanin to 0.58. The authors attribute this to a well-known limitation of immersion-based zebrafish assays: the chorion and vitelline membrane act as uptake barriers, and internal concentrations of a poorly water-soluble peptide like YA-9 may simply never reach the levels needed for visible depigmentation. Studies of small-molecule uptake in embryos have documented internal exposures five- to ninety-fold below nominal bath concentrations.

The upshot is a nuanced but genuinely promising result. YQ-7 and YA-9 are the first sequence-defined tyrosinase-inhibiting peptides isolated from black ginger, they retain activity in synthetic form, they competitively block the pigment enzyme’s active site through structurally coherent interactions, and they suppress basal melanogenesis in living cells without toxicity. Their zebrafish neutrality reflects a delivery problem rather than a failure of mechanism. The researchers propose that rational sequence refinement or novel delivery systems that enhance bioavailability could close the potency gap, positioning these black ginger peptides as a sustainable, plant-derived starting point for the next generation of skin-brightening actives.

Subject of Research: Novel tyrosinase inhibitory peptides from Kaempferia parviflora protein hydrolysate and their anti-melanogenic mechanisms in B16F10 cells and zebrafish

Article Title: Novel tyrosinase inhibitory peptides from Kaempferia parviflora protein hydrolysate with melanin suppression and mechanistic insights from B16F10 cells and zebrafish models

Article References: Sangtanoo, P., Kuptawach, K., Noitang, S., Saisavoey, T., Watsuntorn, W., Nutho, B., Reamtong, O., Ariyawansa, H. A., Karnchanatat, A., & Srimongkol, P. (2026). Novel tyrosinase inhibitory peptides from Kaempferia parviflora protein hydrolysate with melanin suppression and mechanistic insights from B16F10 cells and zebrafish models. Journal of Agriculture and Food Research, 31, Article 103357. https://doi.org/10.1016/j.jafr.2026.103357

Image Credits: AI Generated

DOI: 10.1016/j.jafr.2026.103357

Keywords: tyrosinase inhibition, Kaempferia parviflora, black ginger, bioactive peptides, melanogenesis, hyperpigmentation, B16F10 melanoma cells, molecular docking, competitive inhibition, zebrafish embryos, cosmetic ingredients, bromelain hydrolysis

The significance of the moment is hard to overstate. Sleep is a quantifiable and clinically rich physiological state, making it a natural target for continuous health monitoring ever since wrist-worn actigraphy was first introduced by Kripke and colleagues in 1978. Yet while wearable hardware has evolved at a breakneck pace, the standards for validating these technologies have lagged far behind. Experts have increasingly called for formal guidelines governing how consumer devices that deliver diagnostic assessments and medical advice should be tested. Adoption, meanwhile, has already crossed a tipping point: more than 40 percent of US adults now use wearable devices. As photoplethysmography and oximetry sensors mature, these gadgets are no longer merely counting steps but making claims once reserved for medical equipment.

The study by Alavi and colleagues put the Galaxy Watch through an unusually rigorous test. The investigators enrolled 147 participants and gathered data on two separate nights, comparing the watch’s estimated apnea-hypopnea index against full in-lab polysomnography, the gold standard for sleep apnea diagnosis. The two monitored nights were separated by four to ten nights of at-home recording, a design that aligned directly with the FDA-cleared two-night decision framework while also capturing the natural night-to-night variability of the disorder. The researchers benchmarked the watch not only against conventional respiratory event frequency metrics but also against hypoxic burden, an emerging measure of the cumulative oxygen deprivation a patient experiences during sleep.

The headline numbers are striking. Against the polysomnography-derived apnea-hypopnea index scored at a 4 percent oxygen desaturation threshold, the watch’s estimate achieved an area under the receiver operating characteristic curve of 0.94, with a correlation of 0.87, its strongest diagnostic performance. Even more impressive, among participants classified into the high-risk hypoxic burden stratum, the algorithm achieved 100 percent sensitivity and 100 percent specificity. This suggests that optical photoplethysmography and wrist oximetry are especially discriminative when the cumulative hypoxemic stimulus is large. The performance profile aligns with a hypoxia-based screening approach and hints at reduced discriminatory power for milder disease, where arousals rather than oxygen drops dominate the pathology.

Equally notable was the study’s attention to a well-known weakness of optical sensing: skin pigmentation. Pulse oximeters measure light absorption through tissue, and darker skin tones have historically degraded their accuracy. The investigators conducted structured subgroup analyses across sex, body mass index, age, ethnicity, and objectively measured skin pigmentation. They found consistent sensitivity above 91 percent and consistent specificity across darker skin tones, addressing a vulnerability that has plagued optical pulse oximetry for generations and that regulators have scrutinized intensely in recent years.

But the commentary authors identify serious caveats that temper the enthusiasm. The study population was enriched for individuals with either a prior diagnosis of moderate-to-severe obstructive sleep apnea or a high pre-test probability, defined by a STOP-Bang score of 3 or greater. Of the 147 participants who completed both laboratory nights, 97 had moderate-to-severe sleep apnea on both nights, while only 29 had an apnea-hypopnea index below 15 on both nights. This spectrum bias artificially inflates positive predictive values, which exceeded 95 percent in the study. In a low-prevalence general screening population, the false positive rate would be substantially higher, a statistical reality that could overwhelm sleep clinics with unnecessary referrals.

The raw performance figures at the manufacturer’s default threshold tell a more complicated story. At an estimated apnea-hypopnea index cutoff of 15 events per hour, the device showed high sensitivity of 94.1 percent but a notably modest specificity of only 66.7 percent against the 4 percent oxygen desaturation index, and 65.8 percent against the standard apnea-hypopnea index. That figure stands in contrast to the 87.7 percent specificity reported in the FDA De Novo authorization summary. When the investigators shifted the cutoff to a cohort-optimized threshold of 25.95 events per hour, specificity rose to 94.9 percent but sensitivity fell to 82.4 percent. In other words, the device can be tuned to catch most cases or to avoid most false alarms, but not both simultaneously, and clinicians deploying it must understand exactly where that trade-off sits.

Real-world data quality posed another problem. Among the 147 participants who completed both in-lab polysomnography sessions, 57 lacked valid watch data on one or both laboratory nights because of poor signal quality, motion artifact, or inadequate wrist coupling, an invalidation rate of 38.8 percent during attended studies. The researchers supplemented missing data with home recordings for research purposes, but unwitnessed home recordings remain susceptible to unmeasured confounders such as positional therapy, alcohol consumption, sleep fragmentation, or undiagnosed central apnea events. A wearable that fails to produce usable data in nearly four out of ten supervised sessions highlights the ongoing engineering challenge of sensor displacement and optical signal loss in wrist-worn consumer hardware.

The study also excluded patients with significant cardiac disease, chronic pulmonary disease, movement disorders, and comorbid sleep disorders. These are precisely the comorbid conditions that are common among patients referred for sleep evaluation, meaning the algorithm’s performance in multimorbid populations remains unproven. The US Preventive Services Task Force, moreover, does not currently support screening for obstructive sleep apnea in the absence of symptoms, citing insufficient evidence of screening accuracy and inconsistent evidence on health outcomes. Any wearable-based screening program would therefore operate in a gray zone of preventive medicine, generating findings that guidelines do not yet know how to handle.

The practical implications for clinicians are concrete. Used as a sole screening tool at the default 15 events per hour threshold, the watch would generate a significant number of false positives, burdening downstream sleep clinic resources and confirmatory diagnostic pathways. Confirmatory testing with polysomnography or home sleep apnea testing would still be required before initiating therapy. Yet the commentary authors see genuine value in the device’s ability to identify high-risk individuals with significant hypoxic burden, positioning it as an accessible triage entry point rather than a diagnostic endpoint. In their view, the work by Alavi and colleagues provides a reasonable roadmap for validating emerging wearable devices and algorithms, and industry’s willingness to seek FDA approval for clinical claims is itself an encouraging development. Deployment, they conclude, would still require careful appraisal of positive and negative predictive values within each specific population and clinical setting. The smartwatch has crossed a threshold, but it has not yet arrived at its destination.

Subject of Research: Validation of a consumer smartwatch algorithm for detecting moderate-to-severe obstructive sleep apnea

Article Title: A smart watch crosses the threshold into clinical practice—or not quite yet?

Article References: Khayat, R. N., & Floyd, M. S. (2026). A smart watch crosses the threshold into clinical practice—or not quite yet?. Journal of Clinical Sleep Medicine, 22(1), Article 181. https://doi.org/10.1007/s44470-026-00195-4

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00195-4

Keywords: wearable technology, obstructive sleep apnea, smartwatch, photoplethysmography, sleep medicine, FDA clearance, hypoxic burden, polysomnography, diagnostic validation, screening, oximetry, skin pigmentation

The stakes of this question are anatomical as much as they are social. Dermatology is perhaps the most visually dependent specialty in medicine. A diagnosis of erythema, for example, relies on the recognition of redness, yet redness manifests very differently on pale skin than on deeply pigmented skin, where inflammation may appear violaceous, hyperpigmented, or nearly invisible to the untrained eye. Conditions as common as acne, eczema, psoriasis, and cutaneous lupus can present with subtle colour cues that vary systematically with the amount and distribution of melanin in the epidermis. Melanoma, too, may look markedly different on dark skin, and acral lentiginous melanoma, which arises on the palms, soles, and nail beds, disproportionately affects people with darker complexions. A clinician trained predominantly on images of light skin is therefore at a measurable diagnostic disadvantage when treating the majority of the world’s population, most of whom have intermediate to deeply pigmented skin.

The authors of the new study frame their inquiry within a growing body of literature that has documented persistent representation gaps in mainstream dermatology education. A widely cited 2021 analysis by Adelekun, Onyekaba, and Lipoff published in the Journal of the American Academy of Dermatology evaluated skin colour in dermatology textbooks and found that images of dark skin were substantially underrepresented relative to the composition of the population. That analysis echoed and extended earlier concerns raised by researchers and trainees who noticed that the visual canon of the specialty, accumulated over decades of publishing, skewed overwhelmingly toward lighter complexions. Subsequent work has examined the problem at multiple levels, from medical school curricula to residency training programs to the published literature itself, and has repeatedly found the same pattern: darker skin tones appear less often, appear later in training materials, and appear with less clinical variety.

One response to those documented gaps has been the creation and proliferation of dedicated textbooks on ethnic dermatology and skin of colour. These volumes were conceived precisely to correct the imbalance in general references, assembling clinical photography, pathophysiology, and treatment guidance relevant to patients with richly pigmented skin. There are now several well-established texts in this niche, some of them now in multiple editions, and they have become standard resources for dermatology residents and practicing clinicians who want to improve their diagnostic acumen across the full range of human skin. Given that these books exist specifically to serve populations that general textbooks have underserved, the new research letter poses an important internal question: do these dedicated resources themselves deliver balanced representation across the spectrum of darker skin tones, or do they too have blind spots?

The study, published as a research letter in volume 318 of Archives of Dermatological Research, was designed and conducted by a team spanning two Canadian institutions. Li and Liu, based at the University of British Columbia’s Faculty of Medicine and its Department of Dermatology and Skin Science, carried out the material preparation, data collection, and analysis, while Shi, of the Division of Dermatology at The Ottawa Hospital and the University of Ottawa, contributed to the conception and design of the study. According to the author contributions published with the article, all three authors participated in developing the study concept, commented on earlier versions of the manuscript, and approved the final text. The article was received in October 2025, revised in September 2026, and published on 23 September 2026, following peer review at the long-running dermatological research journal.

Methodologically, research letters in this field typically follow a content-analysis approach: the investigators identify the relevant textbooks, catalog the clinical images they contain, and classify those images by skin tone, often using an established classification system such as the Fitzpatrick scale or the more gradated tools developed specifically to reduce the tendency of observers to lump all darker skin into a single category. Finer-grained classification matters, because treating skin of colour as a monolith can obscure the distinct needs of patients across a wide range of pigmentation levels, from light brown to deep ebony tones. The detailed classification scheme used in the study, along with the underlying data, is provided within the manuscript and its supplementary information files, allowing readers to examine the criteria the authors applied and to replicate or extend the analysis.

Whatever the precise distribution the authors report, the conceptual significance of auditing dedicated textbooks is easy to articulate. Representation gaps in medical imagery are not merely cosmetic. Studies of clinical decision-making suggest that visual pattern recognition is a core component of diagnostic expertise, and that expertise is built through repeated exposure to examples. If a trainee sees twenty images of psoriasis on light skin and two on dark skin, the mental template that forms will be calibrated accordingly. The consequences are tangible: delays in diagnosis, misdiagnosis, and disproportionate disease burden among patients with darker skin have all been documented for conditions ranging from inflammatory disorders to skin cancer. Canadian survey data published in 2022 by Mahmood and colleagues on skin of colour representation in postgraduate dermatology education underscored that trainees themselves perceive these gaps in their formal programs.

The new study also connects to a broader reform movement that has gained momentum in the past several years. Syder and colleagues published a two-part analysis in the Journal of the American Academy of Dermatology documenting gaps in skin of colour content across medical school, residency, and continuing education, describing curricula that treat pigmented skin as an occasional special case rather than an integral part of dermatologic practice. Wilson and colleagues, writing in the International Journal of Women’s Dermatology, analyzed diversity content in the dermatologic literature and issued what they called a call to action, urging journals, educators, and publishers to treat equitable visual representation as a basic quality standard rather than an aspirational goal. Chang and Lipner catalogued resources for skin of colour images to help educators find better material. Against that backdrop, auditing the dedicated textbooks themselves is a logical next step, because these books are the very resources educators turn to when they try to close the gap.

The researchers report that they have no relevant financial or non-financial interests to disclose, and the study was conducted without external funding, which the authors state in their declarations. That independence matters in a conversation that touches on publishing industries with commercial stakes in their back catalogs. Publishers of medical textbooks face real costs in commissioning new clinical photography, obtaining patient consent, and reprinting new editions, and critics have noted that these economic realities can slow the pace at which visual content is refreshed. Independent audits such as this one provide the empirical evidence base that educators, professional societies, and publishers can use to prioritize where new imagery is most needed and to track progress over time.

For clinicians, educators, and patients, the message of the study is ultimately constructive. The existence of dedicated ethnic and skin of colour dermatology textbooks represents real progress in a specialty that for most of its modern history centered its visual teaching on a narrow slice of humanity. Auditing those texts is not an indictment of them but a way of ensuring that the tools built to correct one imbalance do not quietly introduce another. As dermatology’s global patient population continues to demand equitable, expert care, the granularity with which textbooks represent the full spectrum of skin tones will increasingly be seen as a marker of educational quality. The new research letter in Archives of Dermatological Research, available through its publisher with the data supplied in the manuscript and supplementary files, gives the field a rigorous, transparent framework for holding its own most specialized resources to that standard.

Subject of Research: Skin colour representation in dedicated ethnic and skin of colour dermatology textbooks

Article Title: Skin colour representation in dedicated ethnic and skin of colour dermatology textbooks

Article References: Li, M., Liu, W., & Shi, J. (2026). Skin colour representation in dedicated ethnic and skin of colour dermatology textbooks. Archives of Dermatological Research, 318(1), Article 475. https://doi.org/10.1007/s00403-026-04979-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04979-9

Keywords: dermatology, skin of colour, medical education, textbooks, health equity, clinical imaging, diagnosis, representation, skin pigmentation, research letter, medical publishing, curriculum gaps